The higher dose of interferon-beta-1a (Rebif; 44 mcg) appears to effective in patients with clinically isolated syndrome (CIS) suggestive of MS, according to the results of the phase III REFLEX trial (Comi et al. Lancet Neurol 2012;11:33-41).